December 7, 2012 ICON-Eosinophilic Disorders-An Update on HES and CSS

Lanny J. Rosenwasser, M.D. Dee Lyons/Missouri Endowed Chair in Immunology Research

> Professor of Pediatrics Allergy-Immunology Division Childrens Mercy Hospital Kansas City, Missouri

Professor of Pediatrics, Medicine and Basic Science University of Missouri Kansas City School of Medicine



Disclosure Statement Lanny J. Rosenwasser, MD


• RESEARCH STUDIES

Alcon, A-Z, GlaxoSmithKline, Genentech, Novartis MBBH/MacArthur Foundation, National Institutes of Health

- CONSULTANT Alcon, , A-Z, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi-Aventis
- SPEAKERS' BUREAU Alcon, A-Z, Genentech, Novartis

Learning Objectives

- · Understand the biology of eosinophils
- Understand the role of eosinophils in allergic disease, asthma, and eosinophilic disorders
- Understand treatment of eosinophilic disorders and allergy/asthma including the use of biotherapeutics



	Biology of Eosinophils	
Origin	Bone Marrow derived myeloid cell development driven by cytokines IL-3, IL-5, and GMCSF	
Tissue Distribution	Widespread, primarily epithelial and subepithelial tissues, responsive to chemokines for movement and adhesion	
Functions	Host Defense and Tissue Remodeling	
Factors/Product	Cationic Proteins – (MBP, ECP, EDN, EPO) Cytokines, Chemokines, PAF, Prostaglandins Leukotrienes	

Degrees of Eosinophilia

<u>Severity</u>	Level (Eos/ul)	Differential Diagnosis
Mild	500-1000	allergic diseases, atopy, asthma, drug, allergy, bacterial and viral infections
Moderate	1500-5000	Parasitic Infection, HES Churg-Strauss Syndrome, cancers, Sezary's Sydrome
Severe	>5000	HES, eosinophilic leukemia, myeloproliferative disorders, and cancer

Treatment of Eosinophilia

Steroids

• Treat Underlying disorders as primary treatment

• For HES:

Interferon alpha Hydroxyurea Imatinib Anti IL-5 (Mepolizumab, Reslizumab) Anti IL-5 receptor (MEDI-563)

ICON Documents

- iCAALL WAO,AAAAI,ACAAI,EAACI
- Consensus Documents on Critical Topics in Allergy/Immunology
- Advocacy

Causes of Reactive Eosinophilia/HE

Common Causes: Helminth Infections Allergic Reactions Atopic Diseases Drug-Reactions (Allergic or Toxic)

Rare Causes: Chronic Graft-versus-Host Disease Chronic Grait-versus-Host Disease Hodgkin's Disease B or T Coll LymphomaLeukemia Langerhans Cell Histicoptosis Solid Tumors/Malignancy Scables, other infestations Allengic Bronchopulmonary Aspergillosis Chronic Inflammatory Disorders (e.g. IBD) Autoimmune. Diseases Autoimmune Diseases

*In most cases, eosinophilia is attributable to eosinophilopoietic cytokines IBD, inflammatory bowel disease

Eosinophilic Gastrointestinal Disorders (EGID) Eosinophilic Eosphagits Eosinophilic Castro-entertitis Eosinophilic Coltis Eosinophilic Coltis Eosinophilic Pancreatitis Eosinophilic Asches Putmonary Eosinophilic Syndromes Eosinophilic Bronichtis Eosinophilic Bronichtis Eosinophilic Bronichtis Eosinophilic Bronichtis Eosinophilic Plevittis Eosinophilic Endometritis and Myometritis Eosinophilic Endometritis and Myometritis Eosinophilic Budattis Eosinophilic Bonders Eosinophilic Bonders Eosinophilic Bonders Eosinophilic Bonders Eosinophilic Bonders Eosinophilic Syndromes Eosinophilic Pannicultis Eosinophilic Eosinophilic Bonders Eosinophilic Eosinophilic Bonders Eosinophilic Pannicultis Eosinophilic Eosinophilic Bonders Eosinophilic Conditions/Diseases* In addition to the disorders listed in this table, the

Organ-restricted (inflammatory) conditions accompanied by HE

In addition to the disorders listed in this table, there are many other chronic conditions where blood or/and tissue HE is detectable, such as tissue fibrosis, ocular disorders, atopic dermatitis, nead polyposis, interstitial nephritis, and acute neorotizing myocarditis, IgE immunoglobulin E. "Dermatologic conditions including inflammatory reactions are listed in Table 1.

Dermatological Diseases Accompanied by Eosinophilia

ciated with radiotherap

act dermatitis bid hyperplasia with eosinophilia rema of il incy

bid

ac fasciitis lic, polyme lymorphic, and pruritic erup tular folliculitis-all variants

ha toxicum neonatorum bhilic ulcer of the oral mucosa

toparasites including scabies, bed bugs and cutaneous larva migrans)

cell histiocytosis poides and Sezary syndrome ous eosinophil dermatitis


us variants y-related dermatoses

/mphoma langioedema s Wells Syndrome (eosinophilic cellulitis)

nological discours in which examples are a component of the characteristic histological parent and other associated with people at phils in basical itsue acclose and/or by immunostants for their toxic granule proteins, which are departed in taskes in the presence of closeful and other acclosed in the accession of the accession of the accession of the accession of taskes in

Selected Defined Syndromes Associated with Eosinophilia or HE

Gleich Syndrome	Cyclic recurrent angioedema, HE, and elevated (gM, often with clonal T cells regarded as one of several possible clinical presentation of lymphoid HES by some of the faculty members)
Churg-Strauss Syndrome	Necrotizing vasculitis with HE (ANCA+ and ANCA- Subvariants)
Eosinopilia Myalgia Syndrome	Severe myalgia plus HE, often accompanied by neurologic symptoms and skin changes; epidemic cases have been attributed to Lryptophan exposure (Subvariant: Toxic oil syndrome)
Hyper IgE Syndrome	Hereditary immunodeficiency syndrome with HE and elevated levels of IgE, often with eczema and facial anomalies. Known gene mutations: Autosomal dominant, AD-HIES: STA73 mutations Autosomal recessive. AR HIES: DOCK# mutations



Hypereosinophilic syndromes: diagnostic criteria

- Eosinophil counts > 1500/mm³ for at least 6 months, or less than 6 months with evidence of organ damage
- Lack of evidence for parasitic, allergic, or other recognized causes of eosinophilia
- Symptoms and signs of organ system involvement

Hypereosinophilic syndromes: clinical features

Myeloproliferative	Lymphoproliferative
FIP1L1-PDGFRA gene; other as yet unidentified mutations possible	T-cell clone producing Th2 cytokines
Classical HES – males with endomyocardial disease; increased number of atypical mast cells or systemic mast cell disease variant with peripheral blood eosinophilia) or overlap	
ligh serum tryptase level, tissue ibrosis, elevated vitamin B12 evels, splenomegaly and bone narrow biopsies with increased umbers of CD25+ atypical pindle-shaped mast cells	


Clinically Distinguishing Characteristics of the Sub-types of Hypereosinophilic Syndrome (HES)

Myeloproliferative HES	Lymphocytic HES
Cardiac complications	Cutaneous manifestations (pruritus, eczema, erythroderma, urticaria, angioedema)
Anemia and/or thrombocytopenia	Increased serum immunoglobulin E levels
Abnormal leukocyte alkaline phosphatase score	Increased interleukin-5-producing T- cell population with cytogenetic changes
Increased serum vitamin B12	Polyclonal hypergamma-globulinemia
Chromosomal abnormalities Hepatomegaly, splenomegaly Splenomegaly	


Treatment Options for Hypereosinophilic Syndrome


Treatment:


- · Corticosteroids
- Cytotoxic agents (hydroxyurea, vincristine, cyclophosphamide, busulfan, methotrexate, chlorambucil)
- Biological response modifiers
 Interferon-alpha
- Cyclosporine
- Imatinib mesylate
- Mepolizumab





Marc E. Rohenberg, M.D., Ph.D., Amy D. Klion, M.D., Florence E. Roufosse, M.D., Ph.D., Jean Ermanuel Kahn, M.D., Petter F. Weller, M.D., Hans-Uwe Simon, M.D., Ph.D., Lawrence B. Schwartz, M.D., Ph.D., Lamy, J. Resemvasser, M.D., Johannes Ring, M.D., Ph.D., Elaine F. Griffin, D.Phil, Ame I: Haig, B.S., Ngu Li H., Trever, M.S., Logucaline M. Parka, N.B., S. K. D., and Genid J. Gleich, M.D., for the Mepoleumab HES Study Group^a











Classification of Vasculitis

Necrotizing Vasculitis Polyarteritis Nodosa Microscopic Polyangiitis Churg Strauss Syndrome Granulomatous Vasculitis Wegener's Granulomatosis Lymphomatoid Granulomatosis Temporal Arteritis Takaysau's Arteritis Hypersensitivity Vasculitis Drug reaction HSP Infection Auto Immunity Kawasaki's Disease Bechet's Disease

ANCA - Specificity

cANCA Wegener's granulomatosis (Proteinase 3)


pANCA (MPO) (Cathepsin) (Lactoferrin) (Elastase) Microscopic polyangiitis PAN Churg-Strauss syndrome RA Hepatitis HIV Inflammatory bowel disease


Prevalence of ANCA

Disease	cANCA	pANCA
	perce	nt
WG	80	14
MPA	45	45
CSS	10	60
PAN	5	15

Adapted from R.W. Simms, NEJM 339:775-763:1998

Organ systems involved by Churg-Strauss syndrome		
<u>Respiratory tract</u> - Asthma- pulmonary infiltrates, alveolar hemorrhage, sinusitis		
<u>Nervous system</u> - Mononeuritis multiplex, polyneuropathy, cerebral hemorrhage, stoke		
Skin - palpable purpura, skin nodules, urticaria, livedo		
Heart - cardiomyopathy, myocarditis, heart failure, arrhythmia		
Kidney - glomerulonephritis, renal insufficiency, renal infarct		
GI tract - ischemic bowel, pancreatitis, cholecystitis		





Diagnosis of Churg-Strauss Syndrome Historical Perspective

Churg and Strauss, 1951	 Asthma 2) Necrotizing vasculitis of small and medium arteries and veins 3) Eosinophii infiltration around involved vessels and tissues 4) Extravascular granulomas 5) Fibrinoid necrosis of involved tissues
Lanham, 1984	1) Asthma 2) Eosinophilia >1.5 x 107 3) Systemic vasculitis involving 2 or more organs
American College of Rheumatology, 1990	 Asthma 2) Eosinophilia >10% 3) Neuropathy 4) Pulmonary infiltrates 5) Paranasal sinus abnormality 6) Extravascular eosinophil infiltration on biopsy
Chapel Hill Criteria, 1994	 Asthma 2) Eosinophilia 3) Eosinophil rich granulomatous inflammation involving the respiratory tract 4) Necrotizing vasculitis affecting small-to-medium sized vessels

Diagnosis of Churg Strauss Syndrome

• Asthma

- -Atopy • Neuropathy
- Eosinophilia
- Blood or Tissue
- Sinus Abnormalities
- Pulmonary Infiltrates/Vasculitis
- (Visceral Sx, Abnl LFT's, Hypertension)
 <u>Angio and CT for Nodose lesions, positive ANCA</u>

Other Clinical Issues

- Forme Fruste of CSS prodromal SX but not full blown CSS
- Major Differential Diagnosis:
 - HES
 - WG
 - PAN
 - MPA (SNV overlap)

Incidence of Common Vasculitis NHS, UK, 1998-1994

<u>Vasculitis</u>	Annual Incidence per million/G
HV	31
WG	12
CSS	6
MPA	6
PAN	12

Watts et al. Seminar A&R 1995;25:28-34

Treatment of Systemic Vasculitis

Cyclophosphamide Azathioprine With or without Prednisone Therapy continued for one year post-remission Relapses treated as initial course Long Term Remissions

Complications of Treatment of Systemic Vasculitis

- Decreased Marrow Reserve
- Hemorrhagic cystitis
- Nausea
- Herpes zoster
- Sterility
- Lymphoma

Newer Approaches to Therapy of Systemic Vasculitis

TM/Sulfa

Pulse Cyclophosphamide Methotrexate, Azathioprine Mycophenylate mesylate (Cellcept) IVIG Interferon-α-2b, Anti-IgE(Xolair)-CSS Enbrel, Remicade Rituxan




FIG. 1. A, Summary of the changes in circula the IVIg treatment protocol. The time course o protocol is summarized on the *bar graph (bi* bar graph) indicate times of IVIg infusions. g eosinophil count. **B**, Prednisone dose during e phase I and phase II portions of the treatment *m). Arrows* (in A and B) and *asterisks* (on the

Hamilos DL, et al. J Allergy Clin Immunol 88:823-824, 1991




Table 5. Chinear butcome or 94 patients with C55	
Clinical Outcome	No.(%)
Remission of Vasculitis	86/94 (91.5)
Relapse of Vasculitis	22/86 (25.6)
Treatment Failure	8/94 (8.5)
Death during follow-up	23 (24.5)

Guillevin L, et. Al. Medicine 78:26-37, 1999



"It's a very rare disease—it doesn't have a cure. It doesn't even have a spokesperson."



